This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy

Merck & Co. is buying the developer of an experimental antiviral drug designed to prevent the flu, as the drugmaker aims to ...

Cidara's Narrow Spread: The Bidding War Is Over

Cidara Therapeutics, Inc. surges to $217 on a bid by Merck & Co., Inc. valuing shares at $221.50. Learn more about CDTX stock ...

Merck to acquire Cidara for $221.50/share in $9.2 billion deal; CDTX soars

Merck ( MRK) to acquire Cidara Therapeutics ( CDTX) for $221.50 per share in cash, for a total transaction value of ...

Merck bets on flu prevention with $9.2 billion deal for Cidara Therapeutics

Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, the companies said on Friday, gaining access to an experimental drug for flu prevention.
TipRanks on MSN

Argenx removed from Best Ideas List at Wedbush

Wedbush is removing Argenx (ARGX) from the firm’s Best Ideas List. Wedbush remains constructive on the name, but believes the upside isn’t ...
BioPharma Dive

Merck stakes $9.2B on Cidara and its long-acting flu drug

The deal, one of two multibillion-dollar buyouts from Merck this year, centers around a drug that could become an alternative ...
Devdiscourse

IDB, CAF and CDB Launch Debt-for-Resilience Plan for Caribbean At COP30

The newly launched initiative aims to take this mechanism to scale by leveraging guarantees from multilateral development ...
Stocktwits on MSN

Merck To Buy Cidara In $9.2B Deal To Strengthen Antiviral Portfolio

Merck (MRK) said on Friday that it has entered into a definitive agreement to acquire Cidara Therapeutics (CDTX) for about $9.2 billion. Under the deal, Merck will buy Cidara for $221.50 per share in ...